DENVER, July 16 /PRNewswire/ -- Myogen, Inc., a Colorado-based
biopharmaceutical company dedicated to discovering, developing and
commercializing drugs for the treatment of cardiovascular diseases, announced
today the appointment of Alene A. Campbell as Vice President of Corporate
Development. Ms. Campbell has over twenty years of executive management
experience in business development and the pharmaceutical industry. Before
joining Myogen, Ms. Campbell served as Vice President of Corporate Development
of Ribozyme Pharmaceuticals, Inc. Ms. Campbell also served as General Manager
of Ribozyme's genomics business unit from its inception, now a German
headquartered corporation, Atugen AG. Prior to Ribozyme, Ms. Campbell held
various marketing and management positions with Chem-Trak Corporation,
CytoSciences, and Hana Biologics (now Cell Genesys). She holds an MBA from
the University of California, Berkeley.
"Alene brings extensive experience in business and corporate development
coupled with a broad background in strategic management in biotechnology,"
commented Dr. J. William Freytag, President and Chief Executive Officer of
Myogen. "Alene's experience will prove valuable for our future strategic
partnering initiatives."
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of therapeutic drugs for the treatment of
cardiovascular diseases. Cardiovascular diseases are the leading cause of
death and disability in the United States, claiming more than one million
lives annually and having associated healthcare costs of approximately
$200 billion per year. Our academic founders, collaborators and staff have
been working for more than 20 years to define the molecular bases of
cardiovascular disease and to optimize its treatment. We believe that our
expertise provides us with the capability to discover, develop and optimize
therapies that address the underlying mechanisms of cardiovascular disease,
evaluate and in-license product candidates and guide clinical development
efforts. We currently market one product in Europe for the acute treatment of
advanced heart failure, and we have two product candidates in late-stage
clinical development for three cardiovascular indications. In addition, we
have developed a portfolio of molecular therapeutic targets that we believe
play key roles in heart disease. Myogen occupies 22,000 square feet of
laboratory and office space in the Denver, Colorado area and currently has
approximately 40 employees. Please visit our website at http://www.myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
J. William Freytag, Ph.D., President & CEO,
+1-303-464-5221, or Joseph L. Turner, Chief Financial Officer,
+1-303-464-5222, both of Myogen, Inc.
|
